Skip to main content
. Author manuscript; available in PMC: 2021 Apr 22.
Published in final edited form as: Nat Rev Urol. 2020 Aug 28;17(11):637–642. doi: 10.1038/s41585-020-0363-3

Table Two.

The incremental costs (cost of screening and treatment), quality adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) per person screened by age and sex. Reproduced with permission from Rossi et al44

Males Females
40 years 50 years 60 years 40 years 50 years 60 years
Prevalence of RCC 0.14%
(0.08-0.23%)		 0.23%
(0.12-0.37%)		 0.34%
(0.18-
0.54%)		 0.07%
(0.04-0.11%)		 0.09%
(0.05-0.14%)		 0.16%
(0.08-0.25%)
Incremental costs £47.06 £45.69 £44.55 £47.61 £46.99 £46.56
Incremental QALYs 0.00155 0.00205 0.00246 0.000809 0.000937 0.00125
ICER £30,367 £22,277 £18,092 £58,819 £50,160 £37,327